Financials data is unavailable for this security.
View more
Year on year Chosa Oncology AB had revenues fall -98.21% from 4.09m to 73.00k, though the company grew net income from a loss of 33.41m to a smaller loss of 23.94m.
Gross margin | -- |
---|---|
Net profit margin | -171,540.00% |
Operating margin | -161,980.00% |
Return on assets | -28.72% |
---|---|
Return on equity | -31.51% |
Return on investment | -31.51% |
More ▼
Cash flow in SEKView more
In 2023, Chosa Oncology AB increased its cash reserves by 808.07%, or 7.81m. Cash Flow from Investing totalled 15.12m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 1.20m in cash from operations while cash used for financing totalled 8.52m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.3054 |
---|---|
Tangible book value per share | 0.1493 |
More ▼
Balance sheet in SEKView more
Current ratio | 5.97 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼